Free Newsletter
High-priced meds spur dosing debate
What's a drug worth? In the case of Cerezyme, a remedy for a rare inherited enzyme deficiency known as Gaucher disease, the answer is $300,000 a year. But experts are questioning whether lower doses of the med would work as well--besides saving some $200,000 per year per patient.
Pharma companies have faced complaints about prices for years, including accusations that they inflate the required doses to boost sales. When those drugs are super-expensive, like Cerezyme, the debate becomes highly fraught. When a study showed that a half-dose of Genentech's Avastin--which runs $100,000 a year--might be as effective in lung cancer as a full one, some doctors switched. Genentech maintains that doses were set for maximum cancer-fighting.
- read the New York Times article
Related Articles:
Drug makers jack prices up 7.8%. Report
Expensive Herceptin draws fire in UK. Report
Doctors fret about long-term impact of expensive drugs. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: